Part two of the latest Annual Report to the Nation on the Status of Cancer found that in 2019, the national patient economic burden associated with cancer care was $21.09 billion, made up of patient out-of-pocket costs of $16.22 billion and patient time costs—the value of time that patients spend traveling to and from, waiting for, and receiving care—of $4.87 billion.
On Feb. 2, Nature Medicine published the results of a large, randomized, prospective clinical trial in the nascent and some say, fringe, field of chrono-oncology—the study of how natural biological rhythms might impact cancer outcomes.
